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Inherited monogenic disease has an enormous impact on the well-being of children and their families. Over half of the children living
with one of these conditions are without amolecular diagnosis because of the rarity of the disease, themarked clinical heterogeneity, and
the reality that there are thousands of rare diseases for which causative mutations have yet to be identified. It is in this context that in
2010 a Canadian consortiumwas formed to rapidly identify mutations causing a wide spectrum of pediatric-onset rare diseases by using
whole-exome sequencing. The FORGE (Finding of Rare Disease Genes) Canada Consortium brought together clinicians and scientists
from 21 genetics centers and three science and technology innovation centers from across Canada. From nation-wide requests for
proposals, 264 disorders were selected for study from the 371 submitted; disease-causing variants (including in 67 genes not previously
associated with human disease; 41 of these have been genetically or functionally validated, and 26 are currently under study) were iden-
tified for 146 disorders over a 2-year period. Here, we present our experience with four strategies employed for gene discovery and discuss
FORGE’s impact in a number of realms, from clinical diagnostics to the broadening of the phenotypic spectrum of many diseases to the
biological insight gained into both disease states and normal human development. Lastly, on the basis of this experience, we discuss the
way forward for rare-disease genetic discovery both in Canada and internationally.Introduction
Seventy-five percent of rare diseases
affect children and thus have an enor-
mous impact on the well-being of
families.1 A rare disease is defined as
one that affects fewer than 200,000
people in the United States or fewer
than 1 in 2,000 people in Europe;
although individually rare, collec-
tively these conditions affect millions
of children worldwide. Most rare dis-
eases are genetic in origin; the precise
number is unknown, but best esti-
mates suggest that there are at least
7,000, and possibly many more, rare
genetic diseases.2,3 An early and accu-
rate genetic diagnosis is critical to the
optimal care for a child with a rare
genetic disease and their family. How-
ever, diagnosis of a rare genetic disease1Children’s Hospital of Eastern Ontario Research Ins
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contingent upon understanding the
molecular etiology of the disease.
The number of genes known to
harbor pathogenic variants, which
currently account for approximately
half of the estimated 7,000 rare ge-
netic diseases,2 is rapidly increasing
with the application of next-genera-
tion sequencing (NGS) technologies
to rare-disease research.4 In 2010,
Canadian funding agencies Genome
Canada and the Canadian Institutes
for Health Research partnered in a
call for a collaborative national con-
sortium to study rare diseases by using
NGS technology. From this funding
opportunity, the FORGE (Finding
of Rare Disease Genes) Canada
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The American Journal of Humaobjective of rapidly identifying genes
associated with a wide spectrum of
rare pediatric-onset single-gene disor-
ders present in the Canadian popula-
tion over a 2-year period (April 2011
to March 2013). Here, we present the
FORGE network infrastructure, clin-
ical and gene-discovery pipelines,
results, and insight gained from the
study of over 250 rare childhood
genetic diseases.FORGE Canada
The FORGE Canada Consortium was
developed with the concept that co-
operation and collaboration, on both
national and international levels, are
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Figure 1. A Map of Canada Depicts the Location of Participating Clinical Sites and
S&T ICs
Abbreviations are as follows: GQ, Genome Quebec; and S&T ICs, science and technology
innovation centers.population of approximately 35
million people living in ten provinces
and three territories. Many of the
Canadians living with rare genetic
diseases are evaluated by one of the
~95 clinical geneticists working from
one of 21 different genetics centers
spreadacross the tenprovinces.Despite
thiswidegeographicdispersion,almost
all clinical geneticists belong to the
Canadian College of Medical Geneti-
cists, resulting in a tightly knit commu-
nity. In addition to including clinical
geneticists, the 170 FORGE members
consist of pediatric subspecialists, bio-
informaticians, and molecular biolo-
gists with expertise in rare genetic
diseases. International collaborations
with clinicians from 17 different coun-
tries were established on an ad hoc ba-
sis. Each of the major clinical genetics
centers identified a site lead (Figure 1;
Table S1, available online) to ensure na-
tional engagement, anda steering com-
mittee of nine individuals was ap-
pointed to direct all administrative
and operational aspects of the project.
The Children’s Hospital of Eastern
Ontario Research Institute was estab-
lished as the lead institution.
Clinical Pipeline
National calls for disorders to be
studied were emailed to the Canadian810 The American Journal of Human Geneticsclinical genetics and genomics com-
munity with a membership listserv.
Submitted conditions had to be con-
genital or of pediatric onset, be most
likely monogenic and have a mole-
cular etiology not understood, and
affect at least one Canadian person;
appropriate investigations (the stan-
dard of care, including chromosomal
microarray, for the respective prov-
ince) had to have been performed
to exclude known causes. Two-page
applications for each disorder were
evaluated by the steering committee
for likelihood of successful gene dis-
covery by one of four strategies
(Table 1). When necessary, the clinical
network was used for identifying
additional affected individuals before
the disorder entered the pipeline.
Our GE3LS (genomics and its ethical,
environmental, economic, legal, and
social aspects) team developed a
model consent form reflecting core
principles based on best practices,
particularly with regard to the dis-
closure of research results and the
sharing of data and biological samples
within Canada and internationally
(consent templates and supporting
documents are provided in Figure S1).
A total of 371 disorders qualified for
entry into the pipeline; 264 disorders94, 809–817, June 5, 2014representing more than 1,000 Cana-
dian samples and an additional 300
international samples were studied
during the project. The types of disor-
ders studied represented a broad
range of pediatric-onset rare diseases
but were enriched with multiple-
malformation syndromes and neuro-
degenerative disorders (Table S2).
The group of affected individuals
and their families assembled for study
was a remarkable Canadian resource
for gene discovery and was a critical
aspect of the success of FORGE.
Gene-Discovery Pipeline
Once a sufficiently sized set of affected
individuals for gene discovery was
identified, a project team was assem-
bled from investigators who had ex-
pressed an interest in studying the
disorder, and samples were sent for
whole-exome sequencing (WES) to
one of three Genome Canada science
and technology innovation centers
(S&T ICs; Figure 1): McGill University
and Genome Quebec Innovation
Centre (Montreal), The Centre for
Applied Genomics (Toronto), and
The Genome Sciences Centre (Van-
couver). To facilitate communication,
the sharing of data, and the develop-
ment of analysis tools, a national
data coordination center (NDCC) was
established at The Hospital for Sick
Children and the University of Tor-
onto. The 264 rare disorders were stud-
ied by WES analysis of 783 samples.
Exome target enrichment was per-
formed with the Agilent SureSelect
50Mb (V3) All Exon Kit; thereafter,
the majority of sequencing was per-
formed on the Illumina HiSeq 2000,
multiplexing three samples per lane.
After duplicate reads were accounted
for, the mean coverage of coding-
sequence regions ranged from 703 to
2003. The FORGE informatics team
analyzed WES data at each S&T IC by
using very similar pipelines based on
alignment with the Burrows-Wheeler
Aligner,5 removal of duplicate reads
with Picard, local indel realignment
with the Genome Analysis Toolkit,6
variant calling with SAMtools,7 and
annotation with ANNOVAR8 and
custom scripts. Annotations used
regularly included variant functional
Table 1. FORGE Strategies for Gene Discovery
Strategy Sample Characteristics Approach to Analysis
No. of
Disorders
1 multiple unrelated individuals or families affected by the
same very rare but highly recognizable clinical condition
identify a common disease-associated gene or pathway
shared between unrelated affected individuals
32
2a consanguineous families map on the basis of homozygosity to exclude the
majority of the genome
60
2b autosomal-dominant families map to exclude the majority of the genome 19
3 nonconsanguineous families with two or more
affected siblings
identify compound-heterozygous variants
(in the same gene) shared between affected siblings
62
4 single affected individuals with no family history identify deleterious variants in genes with
disease associations
91effect, gene OMIM associations, the
number of internal exomes in which
the variant was seen, the frequency of
gene mutations in control exomes
(for identifying dispensable genes),
genotype counts from the NHLBI
exomes (for determining whether a
variant had been seen in homozygous
form), Genomic Evolutionary Rate
Profiling conservation scores, and
metrics for missense single-nucleo-
tide-variant pathogenicity (SIFT, Poly-
Phen, Mutation Taster, likelihood-
ratio test). Copy-number variants
(CNVs) were called from exome data
with FishingCNV9 and XHMM,10
which was important for identifying
a small number of pathogenic CNVs.
For a given disorder, internal exomes
from the other disorders studied to
that point were used as controls for
CNV calling and for filtering out vari-
ants likely to be technical artifacts.
Only rare variants were considered
candidates for any of the disorders
studied; therefore, variants were
removed from candidate lists if they
were seen at greater than 3% allele
frequency in our control exomes or
greater than 1% allele frequency in
the 1000 Genomes Project or NHLBI
Exome Sequencing Project Exome
Variant Server exomes. Close colla-
boration between the project teams
and bioinformaticians processing the
WES data facilitated variant filtering
and the gene-discovery process.
The project teams performed ex-
periments necessary to validate the
candidate variants as disease causing
within a particular gene and thus
render the disorder explained or‘‘solved.’’ A definitive outcome for a
particular disorder occurred when the
variant under consideration was in a
genepreviouslyknowntocausedisease
(known gene), had been previously
identified and assessed for pathoge-
nicity, or had attributes that allowed
for relatively accurate clinical interpre-
tation andwhen the referring clinician
provided feedback that this explained
the affected individual’s phenotype. It
was more challenging to interpret un-
characterized variants in a gene not
previously associated with disease
(novel gene) as disease causing, and
thus causality was supported with
either genetic or functional data. Dele-
terious-appearing variants in the same
novel gene in unrelated affected indi-
viduals with the same or overlapping
phenotype typically constituted con-
firmation of causality. However,
biochemical validation of a putative
pathological variant in a novel gene
to confirm the functional significance
was considered confirmatory in some
cases, for example, when a delete-
rious-appearing variant in a well-
defined molecular pathway resulted
in a metabolite that was easily
measured with a clinical laboratory
test. In other instances, additional
in vitro and in vivo functional studies
were required. If the identification of
disease-causing variant(s) in a novel
gene was successful, the project team
was responsible for publishing the
findings.
Gene Identification
Of the 264 disorders studied during
the FORGE project, definitively dis-The American Journal of Humaease-causing mutations were identi-
fied to explain 120 disorders, and for
26 disorders, highly likely disease-
causing variants were identified in
novel candidate genes; 118 remain
unexplained. These 146 disorders rep-
resented 67 novel genes and 95
known genes. This total of mutations
in 162 genes for 146 disorders reflects
that on several occasions, mutations
in different genes were found to be
causal in different affected individuals
in a cohort with ostensibly the same
disorder; alternatively, what was
initially seen as one disease in an
affected individual or family was
found to be two or more. Of the 67
identified novel genes with disease-
causing variants (20 have been pub-
lished as of January 2014, see Table
2), 30 have mutations in unrelated
affected individuals with the same
phenotype, 11 have functional evi-
dence in support of disease causation,
and 26 have rare predicted pathogenic
variants that segregate with the dis-
ease and a credible functional link
(based on disease pathway or model
organism data) but are in the process
of validation. The rate of novel-gene
discovery and the overall success rate
differ for the four strategies utilized
(Figure 2) and inform the way to suc-
cessfully investigate the remaining
unsolved rare diseases.
Strategy 1: Multiple Unrelated Individuals
or Families Affected by the Same Disease
Strategy 1 was the most successful
approach for novel-gene discovery
and highlighted the importance of
comprehensive and detailed pheno-
typing, as well as the challenge ofn Genetics 94, 809–817, June 5, 2014 811
Table 2. Gene-Discovery Publications by FORGE Canada as of January 2014
Disorder MIM Category Gene Year
CAPOS syndrome11 601338 1 ATP1A3a 2014
Chudley-McCullough syndrome12 604213 2a GPSM2a 2012
Floating-Harbor syndrome13 136140 1 SRCAP 2012
Hajdu-Cheney syndrome14 102500 1 NOTCH2a 2011
Hereditary spastic paraplegia (complex)15 615033 3 DDHD2 2012
Infantile mitochondrial complex II
and III deficiency16
603485 2a NFS1 2014
Jeune syndrome17 615630 2a IFT172 2013
Infantile myofibromatosis18 228550 1 PDGFRB 2013
Intellectual disability19 613680 2a THOC6 2013
Joubert syndrome20 614970 1 TMEM231 2012
Joubert syndrome21 614615 1 C5ORF42 2012
Leber congenital amaurosis22 608553 2a NMNAT1 2012
Mandibulofacial dysostosis
with microcephaly23
610536 1 EFTUD2 2012
Metaphyseal dysplasia with maxillary
hypoplasia and brachydactyly24
156510 2b RUNX2a 2013
Megalencephaly syndromes25 603387 1 AKT3, PIK3R2,
and PIK3CA
2012
Microcephaly-capillary malformation
syndrome26
614261 1 STAMBP 2013
Multiple intestinal atresia27 243150 2a TTC7A 2013
Nager syndrome28 154400 1 SF3B4 2012
SHORT syndrome29 269880 1 PIK3R1 2013
Weaver syndrome30 277590 1 EZH2 2012
aAlready disease-associated gene found to be associated with a previously undescribed mechanism or
phenotype.rare-disease genetic heterogeneity.
WES from multiple singletons or trios
was analyzed for pathogenic variants
in a gene common to unrelated
affected individuals (two to eight
affected individuals underwent WES
per disorder). Thirty-two disorder co-
horts, both autosomal recessive and
dominant, were studied with this
strategy. Overall, disease-causing
variants were identified in 25 novel
genes (both published and unpub-
lished; 23 validated and two under
study) and 20 known genes for 30
disorder cohorts; for two disorders,
no causative variants were revealed.
Fourteen of the 32 disorders studied
(e.g., Floating-Harbor syndrome13 [MIM
136140], mandibulofacial dysostosis
with microcephaly23 [MIM 610536],
microcephaly-capillary malformation812 The American Journal of Human Geneticssyndrome26 [MIM 614261], multiple
intestinal atresia27 [MIM 243150],
Nager syndrome28 [MIM 154400],
SHORT syndrome29 [MIM 269880],
and Weaver syndrome30 [MIM
277590]) had mutations identified
in a single gene in the majority
of affected individuals. Several osten-
sibly recognizable disorders pre-
sumed to have a single cause had
causative variants identified in multi-
ple genes. For example, mutations
(de novo germline and postzygotic)
were detected in three genes encod-
ing PI3K-AKT pathway proteins in
the megalencephaly-polymicrogyria-
polydactyly-hydrocephalus syndrome
(MIM 603387) cohort.25 Elsewhere,
an unexpected level of genetic
heterogeneity was encountered in a
French Canadian Joubert syndrome94, 809–817, June 5, 2014(MIM 614970 and 614615) cohort
coming from the same region of
Quebec; five novel genes (including
TMEM23120 [MIM 614949] and
C5ORF4221 [MIM 614571]) and three
known genes were identified. In
contrast, our analyses of all avail-
able previously reported individuals
with Fitzsimmons syndrome (MIM
270710) revealed that in this
instance, the syndrome was a combi-
nation of two or more rare diseases
and thus unlikely to exist as a single
entity (data not shown). In this re-
gard, given the level of genetic hetero-
geneity combined with challenging
clinical recognition, it is likely that
gene identification for some and
perhaps many of the remaining recog-
nizable syndromes (e.g., Dubowitz
syndrome [MIM 223370]) will require
significant investment in resources
and broad collaboration to move
forward.
Strategy 2: Single Families with Mapping
Data
A significant proportion of the
genome was excluded from analysis
with the use of mapping data for
both consanguineous and auto-
somal-dominant families (with more
than five members available for
analysis). One or two affected individ-
uals per family underwent WES and
subsequent primary analysis focused
on genetic variants within the map-
ped regions established with either
SNP arrays or the WES data (strategy
2a only). Homozygous mutations
were identified (strategy 2a, Figure 2)
in 37 out of 60 (62%) disorders; 17
of these were mutations in novel
genes (nine validated and eight under
study). For example, homozygous
mutations were identified in IFT172
(MIM 607386), associated with Jeune
syndrome17 (MIM 615630), which
was subsequently validated through
the identification of additional
affected individuals as part of an inter-
national collaboration; in NFS1 (MIM
603485), associated with infantile
mitochondrial complex II and III
deficiency;16 and in THOC6 (MIM
615403), associated with intellectual
disability19 (MIM 613680). The latter
two genes are supported as disease
Figure 2. Outcomes of the 264 Disorders Studied with Each
Strategy
Strategy 1 was used for multiple unrelated individuals or families
affected by the same very rare but highly recognizable clinical
condition (32 disorders); strategy 2a was for consanguineous fam-
ilies (60 disorders); strategy 2b was for autosomal-dominant fam-
ilies (19 disorders); strategy 3 was for nonconsanguineous families
with two or more affected siblings (62 disorders); and strategy 4
was for single affected individuals with no family history (91 dis-
orders).causing by functional
studies. Twenty of the dis-
orders in strategy 2a had
homozygous mutations
identified in known genes.
Some of these findings
expanded the phenotype
beyond that originally re-
cognized, whereas others
were mutations in recently
discovered genes lacking
clinical testing or, as in
the case of SLC52A2 (MIM
607882), associated with
sensory neuropathy31
(MIM 614707), published
while our study was under-
way. Many of the known
genes detected were for
genetically heterogeneous
diseases where clinical
testing had only ruled out
the most commonly in-
volved genes. Five disor-
ders manifesting no strong
candidate homozygousvariant had compound-heterozygous
mutations detected (in known dis-
ease-associated genes CRB1 [MIM
604210] and SYNE1 [MIM 608441],
one validated novel gene, and two
potentially novel genes). Eighteen
of the 60 disorders remained un-
solved (30%); these had no strong or
unambiguous homozygous candidate
variant detected.
The study of moderately sized auto-
somal-dominant families with avail-
able mapping data (we did not require
a LOD score greater than 3 for families
to be included, but usually at least
five informative meiotic events were
required) proved to be challenging.
Out of 19 families, disease-causing
variants in seven (37%) genes were
identified; only one was a potentially
novel gene (and is currently being
functionally validated), and another
was a novel mechanism in a known
disease-associated gene, RUNX2
(MIM 600211).24 Depending on the
resolution of the mapping data,
some disorders were left with more
heterozygous candidate variants than
could be prioritized, whereas others
had no candidate variants identified
within a shared haplotype. Thosewith a well-defined single mapped
region and no candidate variant are
being pursued further by whole-
genome sequencing in the search for
a noncoding mutation.
Strategy 3: Autosomal-Recessive, Non-
consanguineous Families
This approach focused on the identifi-
cation of compound-heterozygous
variants shared between two or more
affected siblings; in some instances,
one parent was also sequenced for
facilitating rapid phasing of variants
in the same gene. Of 62 disorders
studied with this pedigree structure,
disease-causing variants were identi-
fied in 13 novel genes (two validated
and 11 under study) and 15 genes in
which mutations are known to be
associated with human disease (suc-
cess rate of 45%). The majority of the
variants identified were compound
heterozygous (22 out of the 28 disor-
ders), as expected. Other inheritance
patterns included homozygous reces-
sive (3), X-linked (2), and dominant
with suspected parental gonadal
mosaicism (1). Although often a
small number of very rare recessive
variants predicted to affect the pro-
tein (nonsynonymous, frameshift,The American Journal of Human Genetics 9splicing) and shared be-
tween two siblings (in two
to ten genes depending on
the number of siblings and
ethnicity in comparison to
control samples) were iden-
tified, the validation of
novel genes found in only
a single family remains
an ongoing challenge. For
example, analysis of two
siblings with complex he-
reditary spastic paraplegia
(MIM 615033) yielded two
genes with multiple hetero-
zygous variants (potentially
compound heterozygous)
and two genes with homo-
zygous variants. Ultimately,
the disease-associated gene
was tentatively identified
as DDHD2 (MIM 615003)
on the basis of variant
type, rarity, and gene func-
tion and subsequently vali-
dated by the identificationof additional families through inter-
national collaboration.15
Strategy 4: Single Affected Individual with
No Family History
We believe that the scenario of a sin-
gle affected individual with no family
history or mapping information will
be encountered with greater fre-
quency as increasingly rare disorders
are analyzed and clinical exome
sequencing becomes broadly avail-
able. The diagnostic yield of this
approach was explored in the final
year of FORGE, particularly for genet-
ically heterogeneous conditions. We
used WES to study 91 affected indi-
viduals as singletons (67) or trios (24)
and identified seven novel genes
(five validated and two under study)
and 32 known genes as having dis-
ease-causing variants. The success
rate (43%) was similar to that of strat-
egy 3; however, a much larger propor-
tion of known genes was identified,
which is not unexpected given our
inclusion criteria and the fact that
this strategy is not ideal for discovery.
Compound-heterozygous or homo-
zygous (24 genes), heterozygous (14
genes), and X-linked (one gene) muta-
tions were all identified. Thirteen4, 809–817, June 5, 2014 813
known and two novel genes (both
validated) were identified in the 24
trios (success rate of 62%), and 19
known genes and five novel genes
(three validated and two under study)
were identified in the 67 singletons
(success rate of 36%). Despite the
observed difference in success rate
between the trio and singleton
approaches, our experience indicated
that trio analysis did not appear
necessary for the detection of known
disease-causing genes for genetically
heterogeneous conditions because
a single candidate was evident in
the majority of cases before analysis
of the parental WES data. However,
the identification of the two novel
genes with de novo mutations would
not have been readily identified by
singleton sequencing only.
Return of Results to Families and Impact
on Patient Care
An important aspect of this study was
to return the results to participating
families; as front-line care givers, our
team can attest to the significant ben-
efits that a molecular diagnosis can
provide families. We were able to re-
turn a definitive molecular etiology,
including mutations in both novel
and known genes, to hundreds of
families. Validation of suspected path-
ogenic variants in a known disease-
associated gene was often as straight-
forward as having the contributing
clinician review the affected individ-
ual’s clinical presentation in light
of the new genotypic information.
Mutations in genes not previously
associated with human disease were
generally shared with families during
manuscript preparation. For muta-
tions in both known and novel genes,
the contributing clinician discussed
the findings with the family and
confirmed the mutation(s) in a clini-
cally certified molecular diagnostic
laboratory before they were used in
making patient management deci-
sions.
Our consent process for FORGE
informed families that we would not
systematically look at WES data for
incidental (or secondary) findings
but that if we observed a convincing
mutation in a medically actionable814 The American Journal of Human Geneticsgene in childhood, we would share
this result with the family. Of the
>700 exomes analyzed as part of this
project, we had only one instance of
a medically actionable incidental
finding in a child: a previously re-
ported RYR1mutation causing suscep-
tibility to malignant hyperthermia.
As part of the FORGE project, we
explored the larger issue of the return
of incidental findings from genomic
sequencing in pediatric research.
Members of our network, as well as
the affected individuals and families,
were participants in various studies.
Perspectives on the professional duty
to disclose incidental findings were
explored with the use of a question-
naire survey both for parents of chil-
dren involved in pediatric research
and for health professionals.32 The
study revealed that, in general, par-
ents want to receive as much infor-
mation about their child’s health as
possible. Concurrently, we engaged
parents in focus groups to explore per-
ceptions of genetic risks (incidental
findings) from genomic data in a
qualitative study.33 As in the written
survey results, parents believed that
they should be made aware of all re-
sults pertaining to their child’s health
status irrespective of the potential
severity and that they would assume
responsibility for communicating
this information to their child. Thus,
despite the potential negative conse-
quences, respondents perceived the
benefits of receiving all incidental
findings as outweighing the potential
harm. The results of these studies
informed, in part, the first draft of
the statement of ‘‘Principles on the
Return of Research Results and Inci-
dental Findings,’’ now endorsed by
the Quebec Network of Applied Ge-
netic Medicine Board of Directors
and officially adopted in May 2013.34
The effects on patient care of
achieving a definitive molecular diag-
noses during FORGE were often both
broad and far reaching. In a few in-
stances, an available effective therapy
(e.g., enzyme replacement therapy
for a family affected by an atypical
form of Hunter syndrome35 [MIM
309900]) was identified. In several94, 809–817, June 5, 2014cases, medications were tailored on
the basis of the molecular insight
(e.g., a change in antiepileptic medi-
cation for a child with intractable
seizures [MIM 245570] secondary to a
GRIN2A [MIM 138253] mutation36).
The end of the diagnostic odyssey
was an important end point for all
families who were given a diagnosis
during FORGE (many of these families
had been investigated for well over a
decade). A clear diagnosis facilitated
access to services for some children,
both in the school and in the commu-
nity. Screening for complications
could also be tailored for many
affected individuals, and insight into
the clinical ends of the spectrum of a
particular disease informed natural
history. Families were provided with
accurate reproductive counseling,
and prenatal diagnosis could be
offered. Finally, we found that the
psychosocial benefits of diagnostic
clarity for families seeking a reason
for their child’s problems were often
dramatic.
Insights Gained from the Study of
264 Disorders
FORGE set out to identify novel genes
with mutations causing rare diseases
of pediatric onset. Of the 264 disor-
ders studied, 146 have been solved to
date, and these represent 67 genes
not previously associated with human
disease. Four strategies (Table 1) were
used for gene discovery, and the
most successful were for multiple un-
related individuals or families affected
by the same recognizable condition
(strategy 1) and consanguineous fam-
ilies (strategy 2a). The distinct advan-
tage in the former case was the valida-
tion of the novel gene as associated
with disease within the cohort under
study, and in the latter case, the
number of genes with deleterious ho-
mozygous variants was limited by
the degree of consanguinity. However,
in the latter instance, as with the re-
maining strategies, identification of
additional affected individuals or
functional data was needed to support
causality.
Overall, the 67 identified novel
genes (41 validated and 26 candidates
Table 3. 95 Known Disease-Associated Genes Identified during the Study of 264 Disorders
Inheritance Genes
Autosomal
dominant
ACTC1,37 ACVR1,a ARID1B,a COL11A1, EFNB1, EFTUD2a (two proposalsb), EP300,a GRIN2A,a IDS,35 KAT6B,a MLL2,a
MYOC (two proposalsb), NR5A1, NTF4,a OTX2, RPE65, SPTAN1a, SYNGAP1,38,a TERT, WDR36,a and WNT5A
Autosomal
recessive
ACSF3, AGL, AICDA, AIMP1, ALDH6A1,39 ALG3, ASAH1,40 ATM, B4GALNT1, BRCA1, C12orf65, CC2D2A (two proposalsb),
CCBE1, CCDC39, CEP290, COQ9, CORO1A, COX10, CRB1, CYP26C1, DHRS3, FBXL4, FRAS1, GNE, HSD17B441 (two proposalsb),
IGHMBP2, KCTD7, LRP5, LRRC6, MERTK, MTO1, MUSK (two proposalsb), NDUFS2, NGLY1, NNT,42 OFD1, PLA2G6, PLCB4, PMM2,
POMC,43 PYCR1, RAB3GAP1, RARS2, RLBP1, RNF216, RTTN, SACS (four proposalsb), SEPN1, SETX, SIL1 (two proposalsb), SLC25A1,
SLC45A2 and G6PC3 (found together in one family),44 SLC52A2, SPAG1, STAR, SYNE1, TMPRSS6,45 TRPV4,WDR62, and ZMYND10
X-linked ABCD1, AR, CHM, and PRPS1
aDe novo dominant mutations.
bProposal number indicates separate families submitted by different consortium members.from the 264 disorders that entered
the pipeline) represent a success rate
of 16%–25% for novel-gene discovery
for the 2-year period. The rate of
novel-gene discovery decreased over
the period of the project, most likely
because the most promising projects
entered the pipeline earlier. The novel
genes published to date have con-
tributed significantly to our under-
standing of the biological basis of
rare disease and normal human devel-
opment. Two interesting outcomes
from our relatively small subset of
novel genes were (1) the observation
of convergence to a common underly-
ing biological mechanism for overlap-
ping disease phenotypes and (2) that
alterations in the same pathway lead
to very distinct diseases. An example
of the former is the discovery of
mutations in novel genes for two mal-
formation syndromes with overlap-
ping craniofacial features: mandibulo-
facial dysostosis with microcephaly
(EFTUD2)23 and Nager syndrome
(SF3B4).28 Both genes are implicated in
RNA splicing; SF3B4 (MIM 605593)
encodes splicing factor 3B subunit 4,
a component of the U2 pre-mRNA
spliceosomal complex, and EFTUD2
(MIM 603892) encodes U5-116kD, a
highly conserved GTPase with a cen-
tral regulatory role in catalytic RNA
splicing and post-splicing-complex
disassembly. We also observed within
our modest subset of genes how
different alterations of a biological
pathway can result in distinct dis-
eases. For example, SHORT syndrome,
characterized by dysmorphic facies,
lipodystrophy, and short stature, is
caused by mutations in PIK3R1 (MIM171833), and using cell lines derived
from affected individuals, we demon-
strated downregulation of the AKT-
mTOR pathway with the diminished
phosphorylation of downstream tar-
gets.29 In marked distinction to the
SHORT syndrome phenotype, mega-
lencephaly-capillary malformation
syndrome, characterized by over-
growth and cellular proliferation,
was found to be secondary to germ-
line or tissue-specific mosaic muta-
tions disrupting other components
of this pathway and thus resulting in
hyperactivation of the AKT-mTOR
pathway.25 Such discoveries will form
the basis of future investigation into
new biological processes and might
one day enable the configuration of
novel therapies.
One of the most surprising insights
during FORGE was the large propor-
tion of causative variants identified
in genes already known to be asso-
ciated with human disease despite
standard-of-care investigations by our
clinical network (Table 3); these muta-
tions were often associated with the
broadening of the known disease
phenotype. These observations con-
tribute to the growing body of litera-
ture supporting the diagnostic utility
ofWES. The other unexpected finding
was the number of affected indi-
viduals whose disease presentation
represents a conflation of more than
one rare disease,44 suggesting that a
subset of affected individuals in ge-
netics clinics appear to have a novel
and previously undescribed disease
secondary to this phenomenon.
Using the lessons learned through
FORGE Canada, we are now workingThe American Journal of Humato facilitate translation of this geno-
mic technology into our Canadian
genetics clinics.
Finally, how do the 118 (of 264) dis-
orders that remain unsolved (without
a clear candidate gene) inform us re-
garding next steps? A subset of these
will most likely include mutations
not captured by exome sequencing
technologies, e.g., poorly covered cod-
ing regions, noncoding mutations,
and other disease mechanisms; how-
ever, we believe that a significant
portion represents an insufficient
number of affected individuals to
establish disease causation. To facili-
tate the comparison of phenotypes
and genotypes, we established two
important and connected resources.
The first, PhenoTips,46 is a standard-
ized phenotyping tool based on the
internationally recognized Human
Phenotype Ontology.47 This tool al-
lows clinicians to describe an affected
individual with standard terms in less
than 5 min by using a web interface
with a predictive terminology search.
These data are then linked with
genomic data in PhenomeCentral,
an integrated portal developed to
facilitate collaboration and gene
discovery. PhenomeCentral is a cen-
tralized repository for unsolved rare
diseases and uses an automated
matching system that connects users
who contribute data with strong
genotypic and phenotypic similarity.
Large-scale collaboration within
PhenomeCentral should enable WES
results for single affected individuals
or families to become more readily
interpretable and variants in genes to
becomemore easily validated throughn Genetics 94, 809–817, June 5, 2014 815
access to data on thousands of other
affected individuals contributed by
international partners; in this way, it
converts affected individuals studied
via strategy 4 to a virtual strategy 1.
We believe that this freely available
resource will assume a central impor-
tance as the rarity of the remaining
unsolved diseases increases.
Moving Forward
The successful completion of the
activities of the FORGE Canada pro-
ject has provided a coordinated
and sustainable national consortium
focused on the investigation of the
genetic basis of rare human diseases.
Moving forward under a new collabo-
rative project, Care4Rare, we expect to
continue to have a substantial impact
on the diagnostic journey of families
living with rare disease in Canada.
Care4Rare is focused on delivering
two benefits for all Canadians affected
by rare disease: (1) efficient and cost-
effective molecular diagnoses and
(2) a platform for identifying thera-
peutic opportunities for rare disease.
To achieve these benefits, we will
continue our gene-discovery pipeline
to screen for causal mutations under-
lying an additional 350 rare genetic
disorders affecting Canadian families
and facilitate the integration of NGS
into the clinic. Care4Rare will develop
and validate a pipeline to identify
therapeutic opportunities based on
repurposing clinic-ready compounds.
The disorders submitted to FORGE,
but not yet studied, provided the first
samples for study within Care4Rare.
The expertise in WES analysis gained
during FORGE provides a framework
for Care4Rare. The National Data
Coordination Centre infrastructure,
including PhenomeCentral, is in
place and ready for use at the larger
scale necessary for Care4Rare. Impor-
tantly, a number of diseases solved
in FORGE are entering the therapeu-
tic discovery pipeline of Care4Rare.
Finally, the FORGE Canada Con-
sortium has facilitated our oppor-
tunity to become a contributing
project to efforts of the International
Rare Diseases Research Consortium,
thereby ensuring Canada’s contribu-816 The American Journal of Human Geneticstion to this world-wide collaboration
going forward.
Supplemental Data
Supplemental Data include one figure
and two tables and can be found with
this article online at http://dx.doi.org/10.
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